After a strong multi year run, Neurocrine Biosciences no longer looks obviously cheap. The broader valuation checks now point to a stock that sits closer to fair value than to a clear bargain.

• Neurocrine Biosciences has returned 89.9% over the past 5 years, which puts extra weight on whether current expectations are already well reflected in the share price.
• Recent progress with products such as valbenazine and CRENESSITY can support confidence in future cash flows, but ongoing clinical and regulatory risk may still make those expectations sensitive to setbacks.
• The stock scores 3 out of 6 on valuation checks, a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Neurocrine Biosciences' current price fairly reflects this mix of past returns, product progress, and only middling value signals.

Is Neurocrine Biosciences Fairly Priced on Earnings?

The P/E ratio is a useful way to compare Neurocrine Biosciences with other profitable biopharma stocks that already have an earnings base. Neurocrine Biosciences currently trades on a P/E of 26.8x, which is higher than the wider biotechs industry average of 17.6x and slightly above the peer group average of 23.6x. That points to investors paying a premium to the broad sector, but not an extreme one versus closer peers.

The tailored fair P/E for Neurocrine Biosciences, which reflects its margins, size and risk profile, is 28.0x, only modestly above the current 26.8x level. Despite recent positive clinical updates around valbenazine and CRENESSITY that can support sentiment, the share price is not far from what this framework suggests as a reasonable earnings multiple.

Overall, Neurocrine Biosciences appears to be trading at roughly a fair earnings multiple on P/E, rather than being clearly cheap or expensive.

The Neurocrine Biosciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives help connect Neurocrine Biosciences' current P/E and valuation checks with the underlying assumptions that would need to hold for the stock to be worth materially more or less than today. Each narrative links its valuation view to a specific path for Neurocrine Biosciences' growth, margins and risk profile. You can revisit these narratives as new information emerges, and they sit on the company’s Community page for ongoing reference.

One of the top community narratives on Neurocrine Biosciences: 27% undervalued

"Neurocrine continues to focus on treatments for neurological, neuroendocrine, and neuropsychiatric disorders..."

Do you think there's more to the story for Neurocrine Biosciences? Head over to our Community to see what others are saying!

The Bottom Line

For Neurocrine Biosciences, the market multiple view points to a stock that looks about right rather than clearly undervalued or overvalued. The current P/E premium over the broader biotechs sector is modest and largely in line with the tailored fair P/E estimate, so valuation alone may not offer a strong margin of safety or a clear warning sign.

From here, the key question is whether Neurocrine Biosciences can deliver on the expectations embedded in that premium, particularly around the durability of its existing products and execution on the pipeline without meaningful clinical or regulatory setbacks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.